Type 1 diabetes mellitus and multiple sclerosis: Common etiological features

Nature Reviews Endocrinology

Volumn 5, Issue 12, 2009, Pages 655-664

  Handel, Adam E ^a   Handunnetthi, Lahiru ^a   Ebers, George C ^a   Ramaǵopalan, Sreeram V ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VITAMIN D;

DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; EPISTASIS; EPSTEIN BARR VIRUS; GENETIC RISK; HLA SYSTEM; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEASONAL VARIATION; SEX DIFFERENCE;

AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTIPLE SCLEROSIS;

EID: 70849117135     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2009.216     Document Type: Review

References (116)

1. Eizirik, D. L, Colli, M. L. & Ortis, F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev. Endocrinol. 5, 219-226 (2009).
2. Steinman, L. A molecular trio in relapse and remission in multiple sclerosis. Nat Rev. Immunol. doi:10.1038/nri2548
3. Soltesz, G., Patterson, C. C. & Dahlquist, G. Worldwide childhood type 1 diabetes incidencewhat can we learn from epidemiology? Pediatr. Diabetes 8 (Suppl. 6), 6-14 (2007). (Pubitemid 47323762)
4. Pugliatti, M., Sotgiu, S. & Rosati, G. The worldwide prevalence of multiple sclerosis. Clin. Neurol. Neurosurg. 104, 182-191 (2002).
5. Issa, L. L., Leong, G. M. & Eisman, J. A. Molecular mechanism of vitamin D receptor action. Inflammation Res. 47, 451-475 (1998).
6. Wilier, C. J. et al. Timing of birth and risk of multiple sclerosis: population based study. BMJ 330, 120 (2005).
7. Rothwell,P.M.,Staines,A.,Smail,P.,Wadsworth,E.&McKinney,P. SeasonalityofbirthofpatientswithchildhooddiabetesinBritain.BMJ312, 1456-1457(1996).(Pubitemid26170619)
8. Rothwell, P. M. et al. Seasonality of birth in children with diabetes in Europe: multicentre cohort study. European Diabetes Study Group. BMJ 319, 887-888 (1999).
9. Lewy,H.etal.Juvenilemultiplesclerosissimilar- typeIdiabetesmellitushasaseasonalityofmonthofbirthwhichdiffersfromthatinthege neralpopulation.J.Pediatr.Endocrinol.Metab.21,473-477(2008).(Pubitemid351894997)
10. Sadovnick, A. D., Duquette, P., Herrera, B., Yee, I. M. & Ebers, G. C. A timingof-birth effect on multiple sclerosis clinical phenotype. Neurology 69, 60-62 (2007). (Pubitemid 47025205)
11. Lewy, H. et al. Seasonality of month of birth differs between type 1 diabetes patients with pronounced beta-cell autoimmunity and individuals with lesser or no beta-cell autoimmunity. Pediatr. Diabetes 9, 46-52 (2008).
12. Feeney, S. J. et al. Evaluation of ICA512As in combination with other islet cell autoantibodies at the onset of IDDM. Diabetes Care 20, 1403-1407 (1997).
13. Mooney, J. A., Helms, P.J., Joolliffe, I. T. & Smail, P. Seasonality of type 1 diabetes mellitus in children and its modification by weekends and holidays: retrospective observational study. Arch. Dis. Child. 89, 970-973 (2004).
14. Embry, A. E, Snowdon, L. R. & Vieth, R. Vitamin D and seasonal fluctuations of gadoliniumenhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol. 48, 271-272 (2000).
15. Tremlett, H. et al. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology 31, 271-279 (2008).
16. Soilu-Hanninen, M. et al. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 79, 152-157 (2008). (Pubitemid 351236545)
17. Danescu, L. G., Levy, S. & Levy, J. Vitamin D and diabetes mellitus. Endocrine 35, 11-17 (2009).
18. Patterson, C. C., Dahlquist, G. G., Gyurus, E., Green, A. & Soltesz, G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 373, 2027-2033 (2009).
19. Alonso, A. & Hernán, M. A. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71, 129-135 (2008).
20. Wallin, M. T., Page, W. F. & Kurtzke, J. F. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann. Neurol. 55, 65-71 (2004).
21. Gale, E. A. The rise of childhood type 1 diabetes in the 20th century. Diabetes 51, 3353-3361 (2002).
22. Grytten. N. et al. A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway. Neurology 66, 182-186 (2006). (Pubitemid 43970150)
23. Dean, G. et al. Multiple sclerosis in Malta in 1999: an update. J. Neurol. Neurosurg. Psychiatry 73, 256-260 (2002).
24. Schranz, A. G. The epidemiology of diabetes in Malta. Diabetes Metab. Rev. 13, 181-199 (1997).
25. Benedikz, J., Magnusson, H. & Guthmundsson, G. Multiple sclerosis in Iceland, with observations on the alleged epidemic in the Faroe Islands. Ann. Neurol. 36 (Suppl. 2), S175-S179 (1994).
26. Helgason, T., Danielsen, R. & Thorsson, A. V. Incidence and prevalence of type 1 (insulindependent) diabetes mellitus in Icelandic children 1970-1989. Diabetologia 35, 880-883 (1992).
27. Orton, S. M. et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 5, 932-936 (2006).
28. Banwell, B. et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol. 6, 773-781 (2007). (Pubitemid 47238663)
29. Winer,S.etal. TypeIdiabetesandmultiplesclerosispatientstargetisletpluscentralnervoussystemau toantigens;nonimmunizednonobesediabeticmicecandevelopautoimmuneencephalitis.J. Immunol.166,2831-2841(2001).(Pubitemid32173525)
30. Banwell, B. et al. Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. Ann. Neurol. 63, 98-111 (2008). (Pubitemid 351240556)
31. DeLuca, G. C., Williams, K., Evangelou, N., Ebers, G. C. & Esiri, M. M. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 129, 1507-1516 (2006). (Pubitemid 43999383)
32. Winer, S. et al. Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive. Nat Med. 9, 198-205 (2003). (Pubitemid 36227722)
33. Razavi, R. et al. TRPV1+ sensory neurons control beta cell stress and islet inflammation in autoimmune diabetes. Cell 127, 1123-1135 (2006). (Pubitemid 44894522)
34. Persson-Sjogren, S. Neuroinsular complex type I: morphology and frequency in lean and genetically obese mice. Pancreas 23, 40-48 (2001). (Pubitemid 32592074)
35. Persson-Sjogren, S., Zashihin, A. & Forsgren, S. Nerve cells associated with the endocrine pancreas in young mice: an ultrastructural analysis of the neuroinsular complex type I. Histochem.J. 33, 373-378 (2001). (Pubitemid 33078973)
36. Dunning, B. E. & Taborsky, G. J. Jr. Neural control of islet function by norepinephrine and sympathetic neuropeptides. Adv. Exp. Med. Biol. 291, 107-127 (1991).
37. Tillil,H.&Kobberling,J.Age- correctedempiricalgeneticriskestimatesforflrstdegreerelativesofIDDMpatients. Diabetes36,93-99(1987).(Pubitemid18077946)
38. Sadovnick, A. D., Baird, P.A. & Ward, R. H. Multiple sclerosis: updated risks for relatives. Am. J. Med. Genet 29, 533-541 (1988).
39. Ebers, G. C., Sadovnick, A. D. & Risch, N. J. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 377, 150-151 (1995).
40. Kumar,D.etal.North-AmericantwinswithIDDM.Genetic,etiological, andclinicalsignificanceofdiseaseconcordanceaccording-age,zygosity, andtheintervalafterdiagnosisinfirsttwin.Diabetes42,1351-1363(1993). (Pubitemid23259856)
41. Kyvik, K. O., Green, A. & Beck-Nielsen, H. Concordance rates of insulin dependent diabetes mellitus: a population based study of young Danish twins. BMJ 311, 913-917 (1995).
42. Kaprio, J. et al. Concordance for type 1 (insulindependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia 35, 1060-1067 (1992).
43. Willer, C. J., Dyment, D. A., Risch, N. J., Sadovnick, A. D. & Ebers, G. C. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc. Natl Acad. Sci. USA 100, 12877-12882 (2003).
44. Islam, T. et al. Differential twin concordance for multiple sclerosis by latitude of birthplace. Ann. Neurol. 60, 56-64 (2006).
45. Herrera, B. M. & Ebers, G. C. Progress in deciphering the genetics of multiple sclerosis. Curr. Opin. Neurol. 16, 253-258 (2003).
46. Ramagopalan, S. V. et al. Clustering of autoimmune disease in families at high risk for multiple sclerosis? Lancet Neurol. 6, 206-207 (2007).
47. Erlich, H. et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 57, 1084-1092 (2008).
48. International Multiple Sclerosis Genetics Consortium (IMSGC). The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes Immun. 10, 11-14 (2009).
49. Todd, J. A., Bell, J. I. & McDevitt, H. O. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329, 599-604 (1987).
50. Cueca, F. et al. A correlation between the relative predisposition of MHC class Il alleles to type 1 diabetes and the structure of their proteins. Hum. Mol. Genet 10, 2025-2037 (2001).
51. Cheong, K. Y et al. Localization of central MHC genes influencing type I diabetes. Hum. Immunol. 62, 1363-1370 (2001).
52. Koeleman, B. P. et al. Genotype effects and epistasis in type 1 diabetes and HLA-DQ trans dimer associations with disease. Genes Immun. 5, 381-388 (2004).
53. Oksenberg, J. R. et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am. J. Hum. Genet 74, 160-167 (2004).
54. Ramagopalan, S. V. & Ebers, G. C. Epistasis: multiple sclerosis and the major histocompatibility complex. Neurology 72, 566-567 (2009).
55. Lincoln, M. R. et al. Epistasis among HLA-DRBl, HLA-DQAl, and HLA-DQBl loci determines multiple sclerosis susceptibility. Proc. Natl Acad. Sci. USA 106, 7542-7547 (2009).
56. Chao, M. J. et al. HLA class I alleles tag HLADRB1*1501 haplotypes for differential risk in multiple sclerosis susceptibility. Proc. Natl Acad. Sci. USA 105,13069-13074 (2008).
57. Marrosu, M. G. et al. DRBl-DQAl-DQBl loci and multiple sclerosis predisposition in the Sardinian population. Hum. Mol. Genet 7, 1235-1237 (1998).
58. Middleton, D., Menchaca, L., Rood, H. & Komerofsky, R. New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens 61,403-407 (2003).
59. Ramagopalan, S. V. et al. The inheritance of resistance alleles in multiple sclerosis. PLoS Genet 3, 1607-1613 (2007).
60. Zoledziewska, M. et al. Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia. Genes Immun. 10, 15-17 (2009).
61. Hafler, J. P. et al. CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun. 10, 305-310 (2009).
62. Maier, L. M. et al. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet 5, e1000322 (2009).
63. Marrosu, M. G. et al. Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study. Lancet 359, 1461-1465 (2002).
64. Marrosu, M. G. et al. The co-inheritance of type 1 diabetes and multiple sclerosis in Sardinia cannot be explained by genotype variation in the HLA region alone. Hum. Mol. Genet 13, 2919-2924 (2004).
65. Gillespie, K. M. et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet 364,1699-1700 (2004).
66. Kontiainen,S.etal.DifferencesinHLAtypesinchildrenwithinsulin- dependentdiabetesdiagnosedin1960s,1970s,and1980s.Lancet2,219(1988). (Pubitemid18215797)
67. Hermann,R.etal. TemporalchangesinthefrequenciesofHLAgenotypesinpatientswithtype1diabetes- indicationofanincreasedenvironmentalpressure?Diabetologia46,420-425(2003). (Pubitemid36547599)
68. Rewers, M. & Zimmet, P. The rising tide of childhood type 1 diabetes-what is the elusive environmental trigger? Lancet 364, 1645-1647 (2004). (Pubitemid 39458129)
69. Chao, M. J. et al. Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex. Hum. Mol. Genet 18, 261-266 (2009).
70. Tabibzadeh,S.S.,Sivarajah,A.,Carpenter,D.,Ohlsson-Wilhelm,B.M. &Satyaswaroop,P.G.ModulationofHLA- DRexpressioninepithelialcellsbyinterleukin1andestradiol-17beta.J.Clin. Endocrinol.Metab.71,740-747(1990).(Pubitemid20286078)
71. Ramagopalan, S. V. et al. Expression of the multiple sclerosis-associated MHC class II allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet 5, e1000369-e1000369 (2009).
72. Branson, P. G., Ramsay, P. P., Thomson, G. & Barcellos, L. F. Analysis of maternal-offspring HLA compatibility, parentoforigin and noninherited maternal effects for the classical HLA loci in type 1 diabetes. Diabetes Obes. Metab. 11(Suppl. 1), 74-83 (2009).
73. Ebers, G. C. et al. Parentoforigin effect in multiple sclerosis: observations in half-siblings. Lancet 363, 1773-1774 (2004).
74. Herrera, B. M. et al. Parentoforigin effects in MS: observations from avuncular pairs. Neurology 71, 799-803 (2008).
75. Hoppenbrauwers, I. A. et al. Maternal transmission of multiple sclerosis in a Dutch population. Arch. Neurol. 65, 345-348 (2008).
76. Ramagopalan, S. V. et al. Parental transmission of HLA-DRB1*15 in multiple sclerosis. Hum. Genet 122, 661-663 (2008).
77. Bain, S. C., Rowe, B. R., Barnett, A. H. & Todd, J. A. Parental origin of diabetesassociated HLA types in sibling pairs with type 1 diabetes. Diabetes 43, 1462-1468 (1994).
78. Munger, K. L., Levin, L. L., Hollis, B. W., Howard, N. S. & Ascherio, A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296, 2832-2838 (2006). (Pubitemid 44969183)
79. Munger, K. L. et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 62, 60-65 (2004).
80. Hypponen, E., Laara, E., Reunanen, A., Jarvelin, M. R. & Virtanen, S. M. Intake of Vitamin D and risk of type 1 diabetes: a birthcohort study. Lancet 358, 1500-1503 (2001).
81. Zipitis, C. S. & Akobeng, A. K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and metaanalysis. Arch. Ms. Child. 93, 512-517 (2008).
82. Li, X. et al. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adultonset latent autoimmune diabetes (LADA). Diabetes Metab. Res. Rev. 25, 411-416 (2009).
83. Pitocco, D. et al. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset type 1 diabetes (IMDIAB XI). Diabet Med. 23, 920-923 (2006). (Pubitemid 44141083)
84. Wingerchuk, D. M., Lesaux, J., Rice, G. P., Kremenchutzky, M. & Ebers, G. C. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 76, 1294-1296 (2005). (Pubitemid 41208389)
85. Goodin, D. S. The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS ONE 4, e4565 (2009).
86. Ramagopalan, S. V. et al. Association of infectious mononucleosis with multiple sclerosis: a population-based study. Neuroepidemiology 32, 257-262 (2009).
87. Edwards,S.,Zvartau,M.,Clarke,H.,Irving,W.&Blumhardt,L.D. Clinicalrelapsesanddiseaseactivityonmagneticresonanceimagingassociatedwithvir alupperrespiratorytractinfectionsinmultiplesclerosis.J.Neurol.Neurosurg. Psychiatry64,736-741(1998).(Pubitemid28274406)
88. Sibley,W.A.,Bamford,C.R.&Clark,K. Clinicalviralinfectionsandmultiplesclerosis.Lancet1,1313-1315(1985). (Pubitemid15059152)
89. Jun, H. S. & Yoon, J. W. A new look at viruses in type 1 diabetes. Diabetes Metab. Res. Rev. 19, 8-31 (2003).
90. Parkkonen, P. et al. Antibody reactivity to an Epstein-Barr virus BERF4-encoded epitope occurring also in Asp-57 region of HLA-DQ8 beta chain. Childhood Diabetes in Finland Study Group. Clin. Exp. Immunol. 95, 287-293 (1994).
91. Surcel,H.M.,Ilonen,J.,Kaar,M.L.,Hyoty,H.&Leinikki,P. Infectionbymultiplevirusesandlymphocyteabnormalitiesatthediagnosisofdiabetes. ActaPaediatr.Scand.77,471-474(1988).(Pubitemid18164675)
92. Campbell, P. D. et al. Cytotoxic T-iymphocyte-mediated killing of human pancreatic islet cells in vitro. Hum. Immunol. 69, 543-551 (2008).
93. Dahlquist, G. et al. Indications that maternal Coxsackie B virus infection during pregnancy is a risk factor for childhood-onset IDDM. Diabetologia 38, 1371-1373 (1995).
94. Hyoty, H. et al. A prospective study of the role of Coxsackie B and other enterovirus infections in the pathogenesis of IDDM. Childhood Diabetes in Finland (DiMe) Study Group. Diabetes 44, 652-657 (1995).
95. Fuchtenbusch, M., Irnstetter, A., Jager, G. & Ziegler, A. G. No evidence for an association of Coxsackie virus infections during pregnancy and early childhood with development of islet autoantibodies in offspring of mothers or fathers with type 1 diabetes. J. Autoimmun. 17, 333-340 (2001). (Pubitemid 34098417)
96. Viskari, H. R. et al. Matemal first-trimester enterovirus infection and future risk of type 1 diabetes in the exposed fetus. Diabetes 51, 2568-2571 (2002).
97. Yoon, J. W., Bachurski, C. J. & McArthur, R. G. Re: Concept of virus as an etiological agent in the development of insulin-dependent diabetes mellitus. Diabetes Res. Clin. Pract 2, 365-366 (1986).
98. Dotta, F. et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc. Natl Acad. Sci. USA 104, 5115-5120 (2007). (Pubitemid 47186185)
99. Richardson, S. J., Willcox, A., Bone, A. J., Foulis, A. K. & Morgan, N. G. The prevalence of enteroviral capsid protein vpl immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia 52, 1143-1151 (2009).
100. Compston, A. & Coles, A. Multiple sclerosis. Lancet 372, 1502-1517 (2008).
101. Multiple sclerosis international federation. Atlas of MS Database [online] http://www.atlasofms. org/index.aspx (2009).
102. rd edn) [online] http://www.eatlas.idf. orB/at]asff5d.htrnl?id=0 (2009).
103. Ebers, G. C. Environmental factors and multiple sclerosis. Lancet Neurology 7,268-277 (2008).
104. von Herrath, M., Sanda, S. & Herold, K. Type 1 diabetes as a relapsing-remitting disease? Nat Rev. Immunol. 7, 988-994 (2007). (Pubitemid 350166057)
105. Rubio, J. P. et al. Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians. Genes Immun. 9, 624-630 (2008).
106. Ramagopalan, S. V., Anderson, C., Sadovnick, A. D. & Ebers, G. C. Genomewide study of multiple sclerosis. N. Engl. J. Med. 357, 2199-2200 (2007).
107. Qu, H. Q., Montpetit, A., Ge, B., Hudson, T. J. & Polychronakos, C. Toward further mapping of the association between the IL2RA locus and type 1 diabetes. Diabetes 56, 1174-1176 (2007). (Pubitemid 46525085)
108. Todd, J. A. et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39, 857-864 (2007).
109. Nistico, L. et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum. Mol. Genet 5, 1075-1080 (1996).
110. Heggarty, S. et al. CTLA4gene polymorphisms and multiple sclerosis in Northern Ireland. J. Neuroimmunol. 187,187-191 (2007). (Pubitemid 47001548)
111. Greve, B. et al. Multiple sclerosis and the CTLA4 autoimmunity polymorphism CT60: no association in patients from Germany, Hungary and Poland. Mult Sder. 14, 153-158 (2008).
112. Hakonarson, H. & Grant, S. F. Genome-wide association studies in type 1 diabetes, inflammatory bowel disease and other immunemediated disorders. Semin. Immunol. doi:10.1016/j.smim.2009.06.001.
113. Aulchenko, Y. S. et al. Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat Genet 40, 1402-1403 (2008).
114. Ban, M. et al. Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur. J. Hum. Genet 17, 1309-1313 (2009).
115. De Jager, P. L. et al. The role of the CD58 locus in multiple sclerosis. Proc. Natl Acad. Sci. USA 106, 5264-5269 (2009).
116. Hoppenbrouwers, I. A. et al. EVI5 is a risk gene for multiple sclerosis. Genes Immun. 9, 334-337 (2008).